Functional Neurologic Disorder Series - Part 3
Neurology Minute17 Dec 2025

Functional Neurologic Disorder Series - Part 3

In part three of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss causes of functional neurologic disorder.

Show citation:

Hallett M, Aybek S, Dworetzky BA, McWhirter L, Staab JP, Stone J. Functional neurological disorder: new subtypes and shared mechanisms. Lancet Neurol. 2022;21(6):537-550. doi:10.1016/S1474-4422(21)00422-1

Show transcript:

Dr. Gabriela Gilmour: This is Gabriela Gilmour with the Neurology Minute. Jon Stone and I are back to continue with part three of our seven-part series on functional neurological disorder. Today, we will focus on the causes of FND.

So Jon, there have been many advances in our understanding of the mechanism of FND in the last 10, 15 years. And so what do we know about this now?

Dr. Jon Stone: I think the key message I want to get across here is that whereas previously we had a very psychiatric, purely psychiatric view of FND, it used to be called conversion disorder, what we've got now is a multi-perspective view of the mechanisms, which mean that we can understand FND at a kind of neural level or brain circuit level, but we can also still retain the importance of psychological factors, traumatic events. And I think it's also important to separate out, as you've done here with a question, what's the mechanism? How is the symptom happening versus why is it happening? Which often people don't do.

So for this question, how is it happening? How is it that somebody, for example, gets a weak leg? Well, at a very simple level, their brain is disconnecting from their leg and that's what dissociation is. And you can explain that to patients at sort of brain circuit level. We've learned that there are disruptions probably in the circuits in our brain that relate to that sense of agency, the parts of our brain that tell us that our bodies belong to us. And people are particularly interested in an area called the temporary parietal junction.

And at a higher broader level, people are particularly interested in the idea that FND is a disorder that you would expect to happen based on our understanding of the brain as a predictive organ. So if the brain spends its time predicting things, maybe in FND what's gone wrong is this is very strong prediction that the leg is weak or that there's a tremor or that a seizure's about to happen that overrides sensory input telling our brain otherwise.

Dr. Gabriela Gilmour: And I guess to follow into that, you mentioned what is going on. So now can you talk a little bit about why somebody might develop FND or the etiology of FND?

Dr. Jon Stone: I think this helps clinically as well as neurologists, because we can talk about mechanism as we would, for example, with MS as inflammation, but why is there inflammation? So okay, the brain's gone wrong, but why has it gone wrong? And there we need a much more complex view of multiple range of risk factors, predisposing, precipitating, and perpetuating that we know are associated with FND, but vary a lot from person to person. So no one person's the same.

If you've had traumatic experiences in the past, that will make you more prone to dissociation. If you've had other functional disorders, if you have almost certainly some forms of genetics make people predisposed. And then as we said in the last episode, having another neurological condition, so having migraine aura, a physical injury, an infective illness, these are powerful reasons to trigger neurological symptoms. And it's not so much why they happen. It's more why do they get there and get stuck? We all probably have transient functional symptoms actually, but why they get stuck in people with FND for various reasons to do with the way their brains work or their past experiences, or sometimes what happens to them in medical systems.

So developing a very open idea about why someone might have FND really helps you, I think, explain that back to patients and produce individual sort of formulations of the problem.

Dr. Gabriela Gilmour: Yeah. And I often say to my patients, "I don't know exactly why you, why today have this." And that's true in medicine in general. We actually often don't know why anybody develops any medical condition with a few exceptions, but we know about risk factors really.

Dr. Jon Stone: Absolutely. It's one of the reasons I hate the term medically unexplained. Actually, I think FND is perhaps more explained in some ways than some of the other conditions like multiple sclerosis and ALS that we actually deal with where we really don't know why they happen.

Dr. Gabriela Gilmour: Well, we will be back for more Neurology Minute episodes to continue our discussion on FND. Thanks for listening.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(2011)

Bridging the Artificial Intelligence Training Gap - Part 1

Bridging the Artificial Intelligence Training Gap - Part 1

In part one of this series, Dr. Justin Abbatemarco and Dr. Alberto Priori discussed the use of artificial intelligence in neurology among peers, not just trainees.  Show citation:  Vozzi C, Sibilla M,...

10 Sep 2min

September 2026 President Spotlight: Our Next Step in Brain Health

September 2026 President Spotlight: Our Next Step in Brain Health

In the September episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost discuss BrainHealth.com and the AAN's expanding brain health movement.  Stay informed by watching the Pres...

9 Sep 3min

Updates in Neuroinfectious Disease - Part 5

Updates in Neuroinfectious Disease - Part 5

In the fifth episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss dexamethasone and listeria meningitis.

8 Sep 4min

Updates in Neuroinfectious Disease - Part 4

Updates in Neuroinfectious Disease - Part 4

In the fourth episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss the use of dexamethasone in the treatment of pneumococcal meningitis.

7 Sep 5min

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments - Part 1

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments - Part 1

In the first installment of this series, Dr. Aaron Zelikovich and Dr. Bhaskar Roy discuss how emerging treatments for myasthenia gravis compare to one another.  Show citation:  McLaren NP, Rosati M, Z...

4 Sep 1min

National Trends in Medicare Charges and Reimbursement for Inpatient Neurologic Care

National Trends in Medicare Charges and Reimbursement for Inpatient Neurologic Care

Dr. Jason Crowell and Ka-Ho Wong discuss national trends in Medicare reimbursement for inpatient neurologic care.  Show citation:  Wong KH, Castillo M, King J, et al. National Trends in Medicare Charg...

3 Sep 2min

Updates in Neuroinfectious Disease - Part 3

Updates in Neuroinfectious Disease - Part 3

In the third episode of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss HSV encephalitis and dexamethasone.

2 Sep 5min

Updates in Neuroinfectious Disease - Part 2

Updates in Neuroinfectious Disease - Part 2

In part two of this series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss pegivirus-associated encephalomyelitis.

1 Sep 5min

Populärt inom Hälsa

somna-med-henrik
rss-jossan-nina
rss-bara-en-till-om-beroende-medberoende
inga-beiga-morsor
bullfika
rss-vuxna-pa-latsas
not-fanny-anymore
sexnoveller-deluxe
johannes-hansen-podcast
rss-viktmedicinpodden
rss-hos-psykologen
sa-in-i-sjalen
angestpodden
rss-angra-inget-3
rss-basta-livet
sova-med-dan-horning
rss-autismandan
rss-ronden
rss-traningsklubben
tyngre-radio